TY - JOUR
T1 - NIH and NCI support for development of novel therapeutics in gynecologic cancer
T2 - A user's guide
AU - Minig, Lucas
AU - Trimble, Edward L.
AU - Birrer, Michael J.
AU - Kim, Kelly Y.
AU - Takebe, Naoko
AU - Abrams, Jeffrey S.
N1 - Funding Information:
Another tremendous resource is the Cooperative Human Tissue Network (CHTN), which is a network of institutions and hospitals that operates not as a bank but rather as a prospective procurement service. While the tissues may not be readily available, the collection and processing of specimens can be tailored (e.g., fresh, frozen, or fixed; media of choice) according to the specific request of each investigator. Pathology report data are provided along with the tissue specimens, but outcome data are generally not available because these specimens are usually collected from surgical resections taking place after a specimen request has been received and processed. Each request for tissues is reviewed by a diagnostic pathologist who can provide advice and assistance to investigators in selecting the proper tissues to support their research goals. The following tissue distribution data for 2006 shows the types of gynecological cancer and normal tissues that can be obtained through CHTN: 825 cervical samples, 20 endometriosis samples, 1046 endometrium samples, 88 endometrium/myometrium samples, 144 fallopian tube samples, 404 fibroid samples, 37 myometrium samples, 1954 ovary samples, 1674 uterus samples, and 90 vaginal samples. Because CHTN is funded by the Cancer Diagnosis Program at NCI, only a minimal processing fee is charged to investigators for the time and effort involved in collecting, processing, storing, and shipping these research specimens. The application form to request specimens can be found as a link on the CHTN website. X [13] Tissue microarrays which include gynecologic cancers have been made by several of the NCI gynecologic cancer SPOREs and Cancer Centers, the NCI's Center for Cancer Research, as well as the GOG Tissue Bank [14] .
Funding Information:
The NIH and NCI fund evaluation of natural products for prevention, treatment, and symptom control in cancer through the NIH National Center for Complementary and Alternative Medicine (NCCAM) and the NCI Office of Cancer Complementary and Alternative Medicine (OCCAM) [20,21] . The NCI OCCAM has a Research Development and Support Program designed to help investigators identify funding opportunities and provide assistance to applicants as they prepare grant applications. Investigators who wish to develop natural products as novel therapeutics for cancer should consult both the NCCAM and OCCAM web sites and program staff.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/2
Y1 - 2010/2
N2 - The development of novel therapeutics is a lengthy and often tortuous process. It frequently spans the identification of new targets, preclinical validation, discovery and refinement of novel therapies, safety studies, phase O, 1, 2, and 3 trials, and reverse translation. NIH and NCI provide via web sites a variety of resources and research tools of great value to investigators. NCI also provides tissue resources useful for discovery and validation, as well as extensive support for preclinical drug development. The NCI's effective partnership with industry and academia, as well as the ongoing NCI-supported clinical trials network, facilitates clinical development of novel therapeutics. Specialized NCI programs focused on cancer imaging, radiation research, and complementary and alternative medicine, also assist the development of novel agents. Finally, the NIH and the NCI sponsor a variety of grant mechanisms, supporting institutions, consortia, and individuals, which investigators seeking to develop novel therapeutics should make themselves familiar.
AB - The development of novel therapeutics is a lengthy and often tortuous process. It frequently spans the identification of new targets, preclinical validation, discovery and refinement of novel therapies, safety studies, phase O, 1, 2, and 3 trials, and reverse translation. NIH and NCI provide via web sites a variety of resources and research tools of great value to investigators. NCI also provides tissue resources useful for discovery and validation, as well as extensive support for preclinical drug development. The NCI's effective partnership with industry and academia, as well as the ongoing NCI-supported clinical trials network, facilitates clinical development of novel therapeutics. Specialized NCI programs focused on cancer imaging, radiation research, and complementary and alternative medicine, also assist the development of novel agents. Finally, the NIH and the NCI sponsor a variety of grant mechanisms, supporting institutions, consortia, and individuals, which investigators seeking to develop novel therapeutics should make themselves familiar.
KW - Grants
KW - NIH and NCI resources
KW - Novel therapeutics
UR - http://www.scopus.com/inward/record.url?scp=73949118952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73949118952&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2009.10.046
DO - 10.1016/j.ygyno.2009.10.046
M3 - Review article
C2 - 19889449
AN - SCOPUS:73949118952
SN - 0090-8258
VL - 116
SP - 177
EP - 180
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -